PAIN THERAPEUTICS WKN: A2PGL8 ISIN: US14817C1071 Kürzel: SAVA Forum: Aktien Thema: Hauptdiskussion

Wir brauchen mal wieder eine Wende hier

Was jetzt schon wieder ?🤢🤮🤢

https://www.cassavasciences.com/static-files/bf7b91e1-e681-4ce9-be05-fae00e3d642e

Anbei das März Update. Ab Q3 2023 wird es dann wohl richtig spannend hier

Das sind doch gute News

Cassava Sciences Inc Has No Financial Exposure To Silicon Valley Bank Or Silvergate Bank https://www.cassavasciences.com/node/16281/html ... Cassava Sciences, Inc. confirmed today that it has no financial exposure to Silicon Valley Bank or Silvergate Bank. J.P. Morgan serves as Cassava Sciences’ principal commercial bank. ...

Stehen irgendwelche News bald an? Zwischenergebnisse oder ähnliches?

Alle positiven Nachrichten werden gleich wieder verkauft unglaublich

Wenn man vom Teufel spricht 😂

Insider Buy https://www.sec.gov/Archives/edgar/data/1069530/000106953023000011/xslF345X03/certent-form4.xml

Gibt's irgwie mal wieder news etc ? 😁

Cassava Sciences GAAP EPS of -$0.47 beats by $0.11 https://seekingalpha.com/news/3941853-cassava-sciences-gaap-eps-of-0_47-beats-0_11 • Cassava Sciences press release (NASDAQ:SAVA): Q4 GAAP EPS of -$0.47 beats by $0.11. • At December 31, 2022, cash and cash equivalents were $201 million, compared to $233.4 million at December 31, 2021, with no debt. Year-end cash balance included net proceeds of $47.3 million from the sale of 1.7 million shares of common stock completed in November 2022. • Net cash use for operations for the first half of 2023 is expected to be approximately $45 to $50 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.

https://www.globenewswire.com/news-release/2023/02/28/2617230/8339/en/Cassava-Sciences-Reports-Full-year-2022-Financial-Results-and-Operating-Updates.html

https://www.instagram.com/reel/CokiE0IIwDE/?igshid=YmMyMTA2M2Y=

🤷‍♂️🤢🤬

Warum heute der Absturz?